Regulus Therapeutics Inc (NASDAQ:RGLS) – Equities researchers at Leerink Swann upped their Q3 2018 earnings per share estimates for shares of Regulus Therapeutics in a research report issued to clients and investors on Tuesday, August 14th. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.11). Leerink Swann currently has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for Regulus Therapeutics’ Q4 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.45) EPS, FY2019 earnings at ($0.20) EPS, FY2020 earnings at ($0.11) EPS, FY2021 earnings at ($0.11) EPS and FY2022 earnings at ($0.12) EPS.

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, May 16th. Wedbush restated a “hold” rating and issued a $1.00 price target on shares of Regulus Therapeutics in a report on Friday, August 10th. ValuEngine upgraded Regulus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Friday, August 10th. Finally, Wells Fargo & Co lowered their price target on Regulus Therapeutics from $1.50 to $1.00 and set a “market perform” rating for the company in a report on Friday, July 6th. Nine research analysts have rated the stock with a hold rating, The stock currently has a consensus rating of “Hold” and an average price target of $0.96.

Regulus Therapeutics stock opened at $0.29 on Thursday. The stock has a market cap of $22.43 million, a P/E ratio of -0.30 and a beta of 1.44. Regulus Therapeutics has a 52 week low of $0.17 and a 52 week high of $1.52.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%.

A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC raised its holdings in Regulus Therapeutics Inc (NASDAQ:RGLS) by 215.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 137,589 shares of the biopharmaceutical company’s stock after buying an additional 94,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.13% of Regulus Therapeutics worth $143,000 at the end of the most recent quarter. 50.77% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

See Also: Price to Earnings Ratio (PE)

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.